UK's National Institute for Clinical Excellence (NICE) Offers Guidance Supporting Bioventus' EXOGEN Device
Published: Jan 24, 2013
DURHAM, N.C.--(BUSINESS WIRE)--New guidance from a British health agency released earlier this month supports the use of an ultrasound bone healing device that can be an alternative to surgery for thousands of patients with ‘problem’ fractures. The agency, the National Institute for Health and Clinical Excellence (NICE), provides evidence-based guidance about medicines, treatments, procedures and devices that represent the best quality care and which offer the best value for the money for England’s National Health Service (NHS), the world’s largest publicly funded health service. The guidance from NICE assessed both the clinical effects and the potential cost savings of the EXOGEN® Ultrasound Bone Healing System, which uses a unique ultrasound signal to stimulate broken bones to heal naturally, in comparison to surgical management. The product, manufactured by U.S.-based Bioventus LLC and distributed in the UK by Smith & Nephew, has been used worldwide since 1997 and is currently the market leader in the US for fracture stimulation.